ClinicalTrials.gg
CompletedNCT01632345Updated Jul 18, 2019Results posted

A Dose-Ranging Study to Compare Doravirine (MK-1439) Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)

A Phase 2 interventional study of Doravirine and Efavirenz in HIV Infections, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-07-18.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
342
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 75 studies in HIV Infections by Merck & Co., Inc — 1 open to participants now, 2 under way, 1 of them phase 3. HIV Infections · Merck & Co., Inc.

Enrollment
22nd of 66
342 · median 163
Started
2012
with 3 others
Phase 2
25 of 75
1 open now
Registered
63rd of 75
by date

Among the 75 studies in HIV Infections by Merck & Co., Inc, this one is the 22nd largest by enrollment of the 66 interventional ones that give a count, is one of 4 that started in 2012, is one of 25 in phase 2, and was the 63rd registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

1 of the 75 studies in HIV Infections by Merck & Co., Inc is open now. Recruiting first, the newest first:

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in HIV Infections by Merck & Co., Inc, or all of them as a file.
02

Study summary

The hypothesis tested in this study is that doravirine (MK-1439) at the final dose selected is superior to efavirenz, each given in combination with TRUVADA®, as measured by the percentage of participants with CNS events by Week 8. If superiority is established at Week 8, the same hypothesis will be tested for Week 24.

Read the detailed description

Part I - Dose-Ranging. Part I will evaluate the (1) safety and tolerability and (2) efficacy (antiretroviral activity) of 4 doses of doravirine compared with efavirenz, when each is given in combination with TRUVADA® for at least 24 weeks in approximately 200 participants. A single dose of doravirine will be selected for further study after all participants complete the Week 24 visit in Part I. Participants receiving any dose of doravirine in Part I will be switched to the selected doravirine dose and continue in the study for up to 96 weeks, but will not be randomized to Part II.

Part II - Selected Dose. Part II will be initiated after the doravirine dose has been selected as indicated above for Part 1. Approximately 120 additional participants will be randomized in 1:1 ratio to the selected dose of doravirine or efavirenz, each in combination with TRUVADA® for 96 weeks of blinded treatment. Part II will evaluate the safety of the selected dose compared with efavirenz, particularly with regard to central nervous system (CNS) adverse events.

03

Conditions studied

  • HIV Infections

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • -1 positive
  • No previous use of antiretroviral therapy (ART)
  • No signs of active pulmonary disease within 45 days before the start of study treatment
  • Clinically stable with no signs or symptoms of acute infection
  • No change in clinical status or chronic medications for at least 2 weeks before the start of study treatment
  • Participants of agree to remain abstinent in line with their preferred and usual lifestyle or use (or have their partner use) 2 acceptable methods of throughout the study and for 12 weeks post study.
  • Participants not of reproductive potential, not sexually active, whose current partner(s) is not of reproductive potential, or whose sexual activity is exclusively homosexual are eligible without requiring the use of contraception.

Exclusion criteria

Exclusion Criteria:

  • Males planning to impregnate or provide sperm donation for the duration of the study plus an additional 12 weeks. Females pregnant or breast-feeding or expecting to conceive or donate eggs for the duration of the study plus an additional 12 weeks.
  • Received any approved or experimental antiretroviral agents or is anticipated to receive such medications during the study.
  • Use of any immunomodulators or therapy within one month before the study. Short courses of (e.g., for asthma exacerbation) are allowed.
  • Treatment for a viral infection other than , such as , with an agent that is active against HIV
  • HIV resistance to emtricitabine, tenofovir disoproxil fumarate, and/or efavirenz.
  • History of renal or urinary obstructive disease or requires dialysis
  • Active virus (HCV) or Hepatitis B virus (HBV) co-infection
  • History of alcohol or other substance abuse
  • Participation in a study with an compound/device within one month or is anticipating to participate in such a study during this study
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
342 participants (actual)

Study arms

  • Experimental
    Doravirine 25 mg

    Doravirine 25 mg + TRUVADA® Participants in this arm will receive doravirine 25 mg in Part I and the selected doravirine dose (either 25 mg, 50 mg, 100 mg, or 200 mg) in Part II. These participants also receive placebo that matches efavirenz.

    Drug: Doravirine · Drug: TRUVADA® · Drug: Placebo for Doravirine

  • Experimental
    Doravirine 50 mg

    Doravirine 50 mg + TRUVADA® Participants in this arm will receive doravirine 50 mg in Part I and the selected doravirine dose (either 25 mg, 50 mg, 100 mg, or 200 mg) in Part II. These participants also receive placebo that matches efavirenz.

    Drug: Doravirine · Drug: TRUVADA® · Drug: Placebo for Doravirine

  • Experimental
    Doravirine 100 mg

    Doravirine 100 mg + TRUVADA® Participants in this arm will receive doravirine 100 mg in Part I and the selected doravirine dose (either 25 mg, 50 mg, 100 mg, or 200 mg) in Part II. These participants also receive placebo that matches efavirenz.

    Drug: Doravirine · Drug: TRUVADA® · Drug: Placebo for Doravirine

  • Experimental
    Doravirine 200 mg

    Doravirine 200 mg + TRUVADA® Participants in this arm will receive doravirine 200 mg in Part I and the selected doravirine dose (either 25 mg, 50 mg, 100 mg, or 200 mg) in Part II. These participants also receive placebo that matches efavirenz.

    Drug: Doravirine · Drug: TRUVADA® · Drug: Placebo for Doravirine

  • Active comparator
    Efavirenz

    Efavirenz + TRUVADA® Participants in this arm will receive efavirenz in Part I and in Part II. These participants also receive placebo that matches doravirine.

    Drug: Efavirenz · Drug: TRUVADA® · Drug: Placebo for Efavirenz

Interventions

  • Part I: Doravirine 25 mg, 50 mg (25 mg X 2), 100 mg, or 200 mg (100 mg X 2) depending upon randomization, taken orally every morning with or without food for at least 24 weeks. Part II: Selected dose of doravirine depending upon randomization (either 25 mg, 50 mg, 100 mg, or 200 mg) tablet orally every morning with or without food for 96 weeks.

    Also known as: MK-1439

  • Efavirenz 600 mg tablet orally at bedtime taken without food on an empty stomach for 96 weeks

  • DrugTRUVADA®

    Open-label TRUVADA® (fixed combination 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate) tablet taken orally with food in the morning for 96 weeks

  • DrugPlacebo for Doravirine

    Placebo tablets matching doravirine

  • DrugPlacebo for Efavirenz

    Placebo tablets matching efavirenz

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With At Least 1 AE in Weeks 0-24: Doravirine (All Doses) vs Efavirenz (Part I)

    Assessment of the percentage of participants receiving doravirine at all doses (25 mg, 50 mg, 100 mg, or 200 mg), compared with participants receiving efavirenz 600 mg, who had at least 1 AE over 24 weeks of treatment. An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR's product, whether or not considered related to the use of the product.The percentage of participants in any treatment group with at least 1 AE was primarily assessed for Weeks 0-24.

    Time frame: Up to Week 24

  2. Percentage of Participants Who Discontinued Study Therapy Due to AEs in Weeks 0-24: Doravirine (All Doses) vs Efavirenz (Part I)

    Assessment of the percentage of participants receiving doravirine at all doses (25 mg, 50 mg, 100 mg, or 200 mg), compared with participants receiving efavirenz 600 mg, who discontinued therapy due to an AE over 24 weeks of treatment. An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR's product, whether or not considered related to the use of the product.The percentage of participants in any treatment group who discontinued therapy due to an AE was primarily assessed for Weeks 0-24.

    Time frame: Up to Week 24

  3. Percentage of Participants With At Least 1 AE in Weeks 0-24: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)

    Assessment of the percentage of participants receiving doravirine at 100 mg, compared with participants receiving efavirenz 600 mg, who had at least 1 AE over 24 weeks of treatment. An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR's product, whether or not considered related to the use of the product.The percentage of participants in any treatment group with at least 1 AE was assessed for Weeks 0-24.

    Time frame: Up to Week 24

  4. Percentage of Participants With CNS Events by Week 8: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)

    Assessment of the percentage of participants receiving doravirine at 100 mg, compared with participants receiving efavirenz 600 mg, who had CNS events over 8 weeks of treatment. CNS events were pooled and evaluated as pre-specified by the protocol (depression, nightmare, confusional state, suicidal ideation, nervous system disorder, psychotic disorder, abnormal dreams, suicide attempt, acute psychosis, delirium, depressed level of consciousness, hallucination, hallucination auditory, hallucination visual, completed suicide, suicidal behavior, major depression, depressed mood, depressive symptom, insomnia, disturbance in attention, somnolence, dizziness, or concentration impaired). The percentage of participants in either treatment group with CNS events was assessed over Weeks 0-8.

    Time frame: Up to Week 8

  5. Percentage of Participants With CNS Events by Week 24: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)

    Assessment of the percentage of participants receiving doravirine at 100 mg, compared with participants receiving efavirenz 600 mg, who had CNS events over 24 weeks of treatment. CNS events were pooled and evaluated as pre-specified by the protocol (depression, nightmare, confusional state, suicidal ideation, nervous system disorder, psychotic disorder, abnormal dreams, suicide attempt, acute psychosis, delirium, depressed level of consciousness, hallucination, hallucination auditory, hallucination visual, completed suicide, suicidal behavior, major depression, depressed mood, depressive symptom, insomnia, disturbance in attention, somnolence, dizziness, or concentration impaired). The percentage of participants in either treatment group with CNS events was assessed over Weeks 0-24.

    Time frame: Up to Week 24

  6. Percentage of Participants With Virologic Response (HIV-1 RNA) < 40 Copies/mL) at Week 24: Doravirine (All Doses) vs Efavirenz (Part I)

    Assessment of the virologic response to doravirine at all studied doses (25 mg, 50 mg, 100 mg, and 200 mg), compared to efavirenz, each in combination with TRUVADA, as measured by the percentage of participants with plasma HIV-1 RNA \<40 copies/mL at Week 24. HIV RNA levels were determined using the Abbott RealTime HIV-1 Assay, which has a limit of reliable quantification of 40 copies/mL. The percentage of participants in any treatment group with a virologic response was assessed at Week 24. The Non-Completer = Failure (NC=F) approach, in which participants who prematurely discontinued assigned treatment for any reason and were considered as failures thereafter, was used as the primary approach to handle missing data this analysis of efficacy.This primary outcome was analyzed for HIV-1 RNA \<40 copies/mL in Part I.

    Time frame: Week 24

  7. Percentage of Participants With Virologic Response (HIV-1 RNA <40 Copies/mL) at Week 24: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)

    Assessment of the virologic response to doravirine at 100 mg, compared to efavirenz, each in combination with TRUVADA, as measured by the percentage of participants with HIV-1 RNA \<40 copies/mL at Week 24. HIV RNA levels were determined using the Abbott RealTime HIV-1 Assay, which has a limit of reliable quantification of 40 copies/mL. The percentage of participants in any treatment group with a virologic response was assessed at Week 24. The NC=F approach was used as the primary approach to handle missing data this analysis of efficacy. This primary outcome was analyzed for HIV-1 RNA \<40 copies/mL in Part I \& Part II combined.

    Time frame: Week 24

Secondary outcomes

  1. Percentage of Participants With Virologic Response (HIV-1 RNA <40 Copies/mL) at Week 48: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)

    Assessment of the virologic response to doravirine at 100 mg, compared to efavirenz, each in combination with TRUVADA, as measured by the percentage of participants with HIV-1 RNA \<40 copies/mL at Week 48. HIV RNA levels were determined using the Abbott RealTime HIV-1 Assay. The percentage of participants in any treatment group with a virologic response was primarily assessed for Weeks 0-24. The NC=F approach was used as the primary approach to handle missing data this analysis of efficacy. This primary outcome was analyzed for HIV-1 RNA \<40 copies/mL in Part I \& Part II combined.

    Time frame: Week 48

  2. Percentage of Participants With Virologic Response (HIV-1 RNA <40 Copies/mL) at Week 96: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)

    Assessment of the virologic response to doravirine at 100 mg, compared to efavirenz, each in combination with TRUVADA, as measured by the percentage of participants with HIV-1 RNA \<40 copies/mL at Week 96. HIV RNA levels were determined using the Abbott RealTime HIV-1 Assay. The percentage of participants in any treatment group with a virologic response was primarily assessed for Weeks 0-24. The NC=F approach was used as the primary approach to handle missing data this analysis of efficacy. This primary outcome was analyzed for HIV-1 RNA \<40 copies/mL in Part I \& Part II combined.

    Time frame: Week 96

  3. Percentage of Participants With Virologic Response (HIV-1 RNA <200 Copies/mL) at Week 24: Doravirine (All Doses) vs Efavirenz (Part I)

    Assessment of the virologic response to doravirine at all studied doses (25 mg, 50 mg, 100 mg, and 200 mg), compared to efavirenz, each in combination with TRUVADA, as measured by the percentage of participants with plasma HIV-1 RNA \<200 copies/mL at Week 24. HIV RNA levels were determined using the Abbott RealTime HIV-1 Assay.The percentage of participants in any treatment group with a virologic response was assessed at Week 24. The NC=F approach was used as the primary approach to handle missing data for this analysis of efficacy. This primary outcome was analyzed for HIV-1 RNA \<200 copies/mL in Part I.

    Time frame: Week 24

  4. Percentage of Participants With Virologic Response (HIV-1 RNA <200 Copies/mL) at Week 24: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)

    Assessment of the virologic response to doravirine at 100 mg, compared to efavirenz, each in combination with TRUVADA, as measured by the percentage of participants with plasma HIV-1 RNA \<200 copies/mL at Week 24. HIV RNA levels were determined using the Abbott RealTime HIV-1 Assay. The percentage of participants in any treatment group with a virologic response was primarily assessed for Weeks 0-24. The NC=F approach was used as the primary approach to handle missing data for this analysis of efficacy. This secondary outcome was analyzed for HIV-1 RNA \<200 copies/mL in Part I \& Part II combined.

    Time frame: Week 24

  5. Percentage of Participants With Virologic Response (HIV-1 RNA <200 Copies/mL) at Week 48: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)

    Evaluation of the antiretroviral activity of doravirine at 100 mg, compared to efavirenz, each in combination with TRUVADA for 24 weeks, as measured by the percentage of participants with HIV-1 RNA \<200 copies/mL at Week 48. HIV RNA levels were determined using the Abbott RealTime HIV-1 Assay. This primary outcome was analyzed for RNA \<200 copies/mL in Part I \& Part II combined.

    Time frame: Week 48

  6. Percentage of Participants With Virologic Response (HIV-1 RNA <200 Copies/mL) at Week 96: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)

    Assessment of the virologic response to doravirine at 100 mg, compared to efavirenz, each in combination with TRUVADA, as measured by the percentage of participants with plasma HIV-1 RNA \<200 copies/mL at Week 96. HIV RNA levels were determined using the Abbott RealTime HIV-1 Assay. The percentage of participants in any treatment group with a virologic response was primarily assessed for Weeks 0-96. The Non-Completer = Failure (NC=F) approach, in which participants who prematurely discontinued assigned treatment for any reason and were considered as failures thereafter, was used as the primary approach to handle missing data this analysis of efficacy. This primary outcome was analyzed for HIV-1 RNA \<200 copies/mL in Part I \& Part II combined.

    Time frame: Week 96

  7. Change From Baseline in CD4 T Lymphocyte Cell Count at Week 24: Doravirine (All Doses) vs Efavirenz (Part I)

    Evaluation of the change from baseline in the CD4 cell count at Week 24 in participants receiving doravirine at all doses (25 mg, 50 mg, 100 mg, and 200 mg), compared with participants receiving efavirenz 600 mg. The Observed Failure (OF) approach was used to handle missing data, and the Baseline CD4 cell count was carried forward for participants who discontinued assigned treatment due to lack of efficacy.

    Time frame: Baseline, Week 24

  8. Change From Baseline in CD4 Cell Count at Week 24: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)

    Assessment of the change from baseline in the CD4 cell count at Week 24 in participants receiving doravirine at 100 mg, compared with participants receiving efavirenz 600 mg. The OF approach was used to handle missing data, and the Baseline CD4 cell count was carried forward for participants who discontinued assigned treatment due to lack of efficacy.

    Time frame: Baseline, Week 24

  9. Change From Baseline in CD4 Cell Count at Week 48: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)

    Assessment of the change from baseline in the CD4 count at Week 48 in participants receiving doravirine at 100 mg, compared with participants receiving efavirenz 600 mg. The OF approach was used to handle missing data, and the Baseline CD4 cell count was carried forward for subjects who discontinued assigned treatment due to lack of efficacy.

    Time frame: Baseline, Week 48

  10. Change From Baseline in CD4 Cell Count at Week 96: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)

    A secondary endpoint in Part I/II combined was the change from baseline in the CD4 count at Week 96 in participants receiving doravirine at 100 mg, compared with participants receiving efavirenz 600 mg. The OF approach was used to handle missing data, and the Baseline CD4 cell count was carried forward for subjects who discontinued assigned treatment due to lack of efficacy.

    Time frame: Baseline, Week 96

  11. Percentage of Participants With At Least 1 AE in Weeks 0-48: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)

    A secondary outcome in Part I/II combined was the percentage of participants receiving doravirine at 100 mg, compared with participants receiving efavirenz 600 mg, who had at least 1 AE over 48 weeks of treatment. The percentage of participants in any treatment group with at least 1 AE was primarily assessed for Weeks 0-48.

    Time frame: Up to Week 48

  12. Percentage of Participants With At Least 1 AE in Weeks 0-96: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)

    A secondary outcome in Part I/II combined was the percentage of participants receiving doravirine at 100 mg, compared with participants receiving efavirenz 600 mg, who had at least 1 AE over 96 weeks of treatment. The percentage of participants in any treatment group with at least 1 AE was primarily assessed for Weeks 0-96.

    Time frame: Up to Week 96

07

Results

Posted Dec 13, 2017

Participant flow

Randomized Participants
Participant flow — Randomized Participants
MilestonePart I: Doravirine 25 mgPart I: Doravirine 50 mgPart I: Doravirine 100 mgPart I: Doravirine 200 mgPart I: Efavirenz 600 mgPart II: Doravirine 100 mgPart II: Efavirenz 600 mg
Started41434241436666
Completed41434241436666
Not completed0000000
Treatment: Part I
Participant flow — Treatment: Part I
MilestonePart I: Doravirine 25 mgPart I: Doravirine 50 mgPart I: Doravirine 100 mgPart I: Doravirine 200 mgPart I: Efavirenz 600 mgPart II: Doravirine 100 mgPart II: Efavirenz 600 mg
Started414342414300
Treated404342414300
Completed292832333000
Not completed12151081300
Withdrew: Adverse event1421300
Withdrew: Lack of efficacy0101100
Withdrew: Lost to follow-up3213400
Withdrew: Non-compliance with study drug3221000
Withdrew: Physician decision2100100
Withdrew: Pregnancy0100000
Withdrew: Protocol deviation0011000
Withdrew: Withdrawal by subject3441400
Treatment: Part II
Participant flow — Treatment: Part II
MilestonePart I: Doravirine 25 mgPart I: Doravirine 50 mgPart I: Doravirine 100 mgPart I: Doravirine 200 mgPart I: Efavirenz 600 mgPart II: Doravirine 100 mgPart II: Efavirenz 600 mg
Started000006666
Treated000006666
Completed000005555
Not completed000001111
Withdrew: Adverse event0000038
Withdrew: Lost to follow-up0000031
Withdrew: Non-compliance with study drug0000030
Withdrew: Withdrawal by subject0000022

Outcome measures

PrimaryPercentage of Participants With At Least 1 AE in Weeks 0-24: Doravirine (All Doses) vs Efavirenz (Part I)

Assessment of the percentage of participants receiving doravirine at all doses (25 mg, 50 mg, 100 mg, or 200 mg), compared with participants receiving efavirenz 600 mg, who had at least 1 AE over 24 weeks of treatment. An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR's product, whether or not considered related to the use of the product.The percentage of participants in any treatment group with at least 1 AE was primarily assessed for Weeks 0-24.

Time frame:
Up to Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With At Least 1 AE in Weeks 0-24: Doravirine (All Doses) vs Efavirenz (Part I)
Percentage of participantsDoravirine 25 mg: Part IDoravirine 50 mg: Part IDoravirine 100 mg : Part IDoravirine 200 mg: Part IEfavirenz 600 mg: Part I
Percentage of Participants With At Least 1 AE in Weeks 0-24: Doravirine (All Doses) vs Efavirenz (Part I)90.0 (76.3 to 97.2)93.0 (80.9 to 98.5)71.4 (55.4 to 84.3)85.4 (70.8 to 94.4)83.3 (68.6 to 93.0)
Statistical analysis
  • Doravirine 25 mg: Part I vs Efavirenz 600 mg: Part I · Difference (doravirine - efavirenz): 6.7 · 95% CI -9.0 to 22.4A negative value would be considered as favoring doravirine over efavirenz.
  • Doravirine 50 mg: Part I vs Efavirenz 600 mg: Part I · Difference (doravirine - efavirenz): 9.7 · 95% CI -4.6 to 24.9A negative value would be considered as favoring doravirine over efavirenz.
  • Doravirine 100 mg : Part I vs Efavirenz 600 mg: Part I · Difference (doravirine - efavirenz): -11.9 · 95% CI -27.9 to 6.3A negative value would be considered as favoring doravirine over efavirenz.
  • Doravirine 200 mg: Part I vs Efavirenz 600 mg: Part I · Difference (doravirine - efavirenz): 2.0 · 95% CI -14.5 to 18.4A negative value would be considered as favoring doravirine over efavirenz.
PrimaryPercentage of Participants Who Discontinued Study Therapy Due to AEs in Weeks 0-24: Doravirine (All Doses) vs Efavirenz (Part I)

Assessment of the percentage of participants receiving doravirine at all doses (25 mg, 50 mg, 100 mg, or 200 mg), compared with participants receiving efavirenz 600 mg, who discontinued therapy due to an AE over 24 weeks of treatment. An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR's product, whether or not considered related to the use of the product.The percentage of participants in any treatment group who discontinued therapy due to an AE was primarily assessed for Weeks 0-24.

Time frame:
Up to Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants Who Discontinued Study Therapy Due to AEs in Weeks 0-24: Doravirine (All Doses) vs Efavirenz (Part I)
Percentage of participantsDoravirine 25 mg: Part IDoravirine 50 mg: Part IDoravirine 100 mg: Part IDoravirine 200 mg: Part IEfavirenz 600 mg: Part I
Percentage of Participants Who Discontinued Study Therapy Due to AEs in Weeks 0-24: Doravirine (All Doses) vs Efavirenz (Part I)2.5 (0.1 to 13.2)7.0 (1.5 to 19.1)2.4 (0.1 to 12.6)0.0 (0.0 to 8.6)4.8 (0.6 to 16.2)
Statistical analysis
  • Doravirine 25 mg: Part I vs Efavirenz 600 mg: Part I · Difference (doravirine - efavirenz): -2.3 · 95% CI -13.7 to 8.8A negative value would be considered as favoring doravirine over efavirenz.
  • Doravirine 50 mg: Part I vs Efavirenz 600 mg: Part I · Difference (doravirine - efavirenz): 2.2 · 95% CI -9.9 to 14.7A negative value would be considered as favoring doravirine over efavirenz.
  • Doravirine 100 mg: Part I vs Efavirenz 600 mg: Part I · Difference (doravirine - efavirenz): -2.4 · 95% CI -13.8 to 8.2A negative value would be considered as favoring doravirine over efavirenz.
  • Doravirine 200 mg: Part I vs Efavirenz 600 mg: Part I · Difference (doravirine - efavirenz): -4.8 · 95% CI -15.9 to 4.1A negative value would be considered as favoring doravirine over efavirenz.
PrimaryPercentage of Participants With At Least 1 AE in Weeks 0-24: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)

Assessment of the percentage of participants receiving doravirine at 100 mg, compared with participants receiving efavirenz 600 mg, who had at least 1 AE over 24 weeks of treatment. An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR's product, whether or not considered related to the use of the product.The percentage of participants in any treatment group with at least 1 AE was assessed for Weeks 0-24.

Time frame:
Up to Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With At Least 1 AE in Weeks 0-24: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)
Percentage of participantsDoravirine 100 mg: Part I/II (Combined)Efavirenz 600 mg: Part I/II (Combined)
Percentage of Participants With At Least 1 AE in Weeks 0-24: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)75.0 (65.7 to 82.8)85.2 (77.1 to 91.3)
Statistical analysis
  • Doravirine 100 mg: Part I/II (Combined) vs Efavirenz 600 mg: Part I/II (Combined) · Difference: -10.2 · 95% CI -20.9 to 0.5A negative value would be considered as favoring doravirine over efavirenz.
PrimaryPercentage of Participants With CNS Events by Week 8: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)

Assessment of the percentage of participants receiving doravirine at 100 mg, compared with participants receiving efavirenz 600 mg, who had CNS events over 8 weeks of treatment. CNS events were pooled and evaluated as pre-specified by the protocol (depression, nightmare, confusional state, suicidal ideation, nervous system disorder, psychotic disorder, abnormal dreams, suicide attempt, acute psychosis, delirium, depressed level of consciousness, hallucination, hallucination auditory, hallucination visual, completed suicide, suicidal behavior, major depression, depressed mood, depressive symptom, insomnia, disturbance in attention, somnolence, dizziness, or concentration impaired). The percentage of participants in either treatment group with CNS events was assessed over Weeks 0-8.

Time frame:
Up to Week 8
Reported as:
Number · Percentage of participants
Percentage of Participants With CNS Events by Week 8: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)
Percentage of participantsDoravirine 100 mg: Part I/II (Combined)Efavirenz 600 mg: Part I/II (Combined)
Percentage of Participants With CNS Events by Week 8: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)24.1 (16.4 to 33.3)44.4 (34.9 to 54.3)
Statistical analysis
  • Doravirine 100 mg: Part I/II (Combined) vs Efavirenz 600 mg: Part I/II (Combined) · Miettinen and Nurminen method · p = 0.002 (Superiority analysis) · Difference (doravirine - efavirenz): -20.4 · 95% CI -32.4 to -7.8A negative value would be considered as favoring doravirine over efavirenz.
PrimaryPercentage of Participants With CNS Events by Week 24: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)

Assessment of the percentage of participants receiving doravirine at 100 mg, compared with participants receiving efavirenz 600 mg, who had CNS events over 24 weeks of treatment. CNS events were pooled and evaluated as pre-specified by the protocol (depression, nightmare, confusional state, suicidal ideation, nervous system disorder, psychotic disorder, abnormal dreams, suicide attempt, acute psychosis, delirium, depressed level of consciousness, hallucination, hallucination auditory, hallucination visual, completed suicide, suicidal behavior, major depression, depressed mood, depressive symptom, insomnia, disturbance in attention, somnolence, dizziness, or concentration impaired). The percentage of participants in either treatment group with CNS events was assessed over Weeks 0-24.

Time frame:
Up to Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With CNS Events by Week 24: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)
Percentage of participantsDoravirine 100 mg: Part I/II (Combined)Efavirenz 600 mg: Part I/II (Combined)
Percentage of Participants With CNS Events by Week 24: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)26.9 (18.8 to 36.2)47.2 (37.5 to 57.1)
Statistical analysis
  • Doravirine 100 mg: Part I/II (Combined) vs Efavirenz 600 mg: Part I/II (Combined) · Miettinen and Nurminen method · p = 0.002 (Superiority analysis) · Difference (doravirine - efavirenz): -20.4 · 95% CI -32.6 to -7.5A negative value would be considered as favoring doravirine over efavirenz.
PrimaryPercentage of Participants With Virologic Response (HIV-1 RNA) < 40 Copies/mL) at Week 24: Doravirine (All Doses) vs Efavirenz (Part I)

Assessment of the virologic response to doravirine at all studied doses (25 mg, 50 mg, 100 mg, and 200 mg), compared to efavirenz, each in combination with TRUVADA, as measured by the percentage of participants with plasma HIV-1 RNA \<40 copies/mL at Week 24. HIV RNA levels were determined using the Abbott RealTime HIV-1 Assay, which has a limit of reliable quantification of 40 copies/mL. The percentage of participants in any treatment group with a virologic response was assessed at Week 24. The Non-Completer = Failure (NC=F) approach, in which participants who prematurely discontinued assigned treatment for any reason and were considered as failures thereafter, was used as the primary approach to handle missing data this analysis of efficacy.This primary outcome was analyzed for HIV-1 RNA \<40 copies/mL in Part I.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Virologic Response (HIV-1 RNA) < 40 Copies/mL) at Week 24: Doravirine (All Doses) vs Efavirenz (Part I)
Percentage of participantsDoravirine 25 mg: Part IDoravirine 50 mg: Part IDoravirine 100 mg: Part IDoravirine 200 mg: Part IEfavirenz 600 mg: Part I
Percentage of Participants With Virologic Response (HIV-1 RNA) < 40 Copies/mL) at Week 24: Doravirine (All Doses) vs Efavirenz (Part I)80.0 (64.4 to 90.9)74.4 (58.8 to 86.5)71.4 (55.4 to 84.3)80.5 (65.1 to 91.2)64.3 (48.0 to 78.4)
Statistical analysis
  • Doravirine 25 mg: Part I vs Efavirenz 600 mg: Part I · Difference in % response: 15.7 · 95% CI -4.1 to 34.4A positive value would be considered as favoring doravirine over efavirenz.
  • Doravirine 50 mg: Part I vs Efavirenz 600 mg: Part I · Difference in % response: 10.0 · 95% CI -9.6 to 29.1A positive value would be considered as favoring doravirine over efavirenz.
  • Doravirine 100 mg: Part I vs Efavirenz 600 mg: Part I · Difference in % response: 6.6 · 95% CI -13.2 to 26.0A positive value would be considered as favoring doravirine over efavirenz.
  • Doravirine 200 mg: Part I vs Efavirenz 600 mg: Part I · Difference in % response: 15.9 · 95% CI -3.4 to 34.4A positive value would be considered as favoring doravirine over efavirenz.
PrimaryPercentage of Participants With Virologic Response (HIV-1 RNA <40 Copies/mL) at Week 24: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)

Assessment of the virologic response to doravirine at 100 mg, compared to efavirenz, each in combination with TRUVADA, as measured by the percentage of participants with HIV-1 RNA \<40 copies/mL at Week 24. HIV RNA levels were determined using the Abbott RealTime HIV-1 Assay, which has a limit of reliable quantification of 40 copies/mL. The percentage of participants in any treatment group with a virologic response was assessed at Week 24. The NC=F approach was used as the primary approach to handle missing data this analysis of efficacy. This primary outcome was analyzed for HIV-1 RNA \<40 copies/mL in Part I \& Part II combined.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Virologic Response (HIV-1 RNA <40 Copies/mL) at Week 24: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)
Percentage of participantsDoravirine 100 mg: Part I/II (Combined)Efavirenz 600 mg: Part I/II (Combined)
Percentage of Participants With Virologic Response (HIV-1 RNA <40 Copies/mL) at Week 24: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)72.9 (63.4 to 81.0)73.1 (63.8 to 81.2)
Statistical analysis
  • Doravirine 100 mg: Part I/II (Combined) vs Efavirenz 600 mg: Part I/II (Combined) · Difference in % response: -0.5 · 95% CI -13.2 to 11.2A positive value would be considered as favoring doravirine over efavirenz.
SecondaryPercentage of Participants With Virologic Response (HIV-1 RNA <40 Copies/mL) at Week 48: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)

Assessment of the virologic response to doravirine at 100 mg, compared to efavirenz, each in combination with TRUVADA, as measured by the percentage of participants with HIV-1 RNA \<40 copies/mL at Week 48. HIV RNA levels were determined using the Abbott RealTime HIV-1 Assay. The percentage of participants in any treatment group with a virologic response was primarily assessed for Weeks 0-24. The NC=F approach was used as the primary approach to handle missing data this analysis of efficacy. This primary outcome was analyzed for HIV-1 RNA \<40 copies/mL in Part I \& Part II combined.

Time frame:
Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With Virologic Response (HIV-1 RNA <40 Copies/mL) at Week 48: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)
Percentage of participantsDoravirine 100 mg: Part I/II (Combined)Efavirenz 600 mg: Part I/II (Combined)
Percentage of Participants With Virologic Response (HIV-1 RNA <40 Copies/mL) at Week 48: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)77.8 (68.8 to 85.2)79.4 (70.5 to 86.6)
Statistical analysis
  • Doravirine 100 mg: Part I/II (Combined) vs Efavirenz 600 mg: Part I/II (Combined) · Difference in % response: -1.9 · 95% CI -12.9 to 9.2A positive value would be considered as favoring doravirine over efavirenz.
SecondaryPercentage of Participants With Virologic Response (HIV-1 RNA <40 Copies/mL) at Week 96: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)

Assessment of the virologic response to doravirine at 100 mg, compared to efavirenz, each in combination with TRUVADA, as measured by the percentage of participants with HIV-1 RNA \<40 copies/mL at Week 96. HIV RNA levels were determined using the Abbott RealTime HIV-1 Assay. The percentage of participants in any treatment group with a virologic response was primarily assessed for Weeks 0-24. The NC=F approach was used as the primary approach to handle missing data this analysis of efficacy. This primary outcome was analyzed for HIV-1 RNA \<40 copies/mL in Part I \& Part II combined.

Time frame:
Week 96
Reported as:
Number · Percentage of participants
Percentage of Participants With Virologic Response (HIV-1 RNA <40 Copies/mL) at Week 96: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)
Percentage of participantsDoravirine 100 mg: Part I/II (Combined)Efavirenz 600 mg: Part I/II (Combined)
Percentage of Participants With Virologic Response (HIV-1 RNA <40 Copies/mL) at Week 96: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)75.0 (65.7 to 82.8)75.9 (66.7 to 83.6)
Statistical analysis
  • Doravirine 100 mg: Part I/II (Combined) vs Efavirenz 600 mg: Part I/II (Combined) · Difference in % response: -0.8 · 95% CI -12.4 to 10.7A positive value would be considered as favoring doravirine over efavirenz.
SecondaryPercentage of Participants With Virologic Response (HIV-1 RNA <200 Copies/mL) at Week 24: Doravirine (All Doses) vs Efavirenz (Part I)

Assessment of the virologic response to doravirine at all studied doses (25 mg, 50 mg, 100 mg, and 200 mg), compared to efavirenz, each in combination with TRUVADA, as measured by the percentage of participants with plasma HIV-1 RNA \<200 copies/mL at Week 24. HIV RNA levels were determined using the Abbott RealTime HIV-1 Assay.The percentage of participants in any treatment group with a virologic response was assessed at Week 24. The NC=F approach was used as the primary approach to handle missing data for this analysis of efficacy. This primary outcome was analyzed for HIV-1 RNA \<200 copies/mL in Part I.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Virologic Response (HIV-1 RNA <200 Copies/mL) at Week 24: Doravirine (All Doses) vs Efavirenz (Part I)
Percentage of participantsDoravirine 25 mg: Part IDoravirine 50 mg: Part IDoravirine 100 mg: Part IDoravirine 200 mg: Part IEfavirenz 600 mg: Part I
Percentage of Participants With Virologic Response (HIV-1 RNA <200 Copies/mL) at Week 24: Doravirine (All Doses) vs Efavirenz (Part I)85.0 (70.2 to 94.3)83.7 (69.3 to 93.2)92.9 (80.5 to 98.5)90.2 (76.9 to 97.3)81.0 (65.9 to 91.4)
Statistical analysis
  • Doravirine 25 mg: Part I vs Efavirenz 600 mg: Part I · Difference in % response: 4.5 · 95% CI -12.5 to 21.5A positive value would be considered as favoring doravirine over efavirenz.
  • Doravirine 50 mg: Part I vs Efavirenz 600 mg: Part I · Difference in % response: 2.8 · 95% CI -13.9 to 19.8A positive value would be considered as favoring doravirine over efavirenz.
  • Doravirine 100 mg: Part I vs Efavirenz 600 mg: Part I · Difference in % response: 12.2 · 95% CI -2.5 to 28.0A positive value would be considered as favoring doravirine over efavirenz.
  • Doravirine 200 mg: Part I vs Efavirenz 600 mg: Part I · Difference in % response: 9.5 · 95% CI -6.2 to 25.7A positive value would be considered as favoring doravirine over efavirenz.
SecondaryPercentage of Participants With Virologic Response (HIV-1 RNA <200 Copies/mL) at Week 24: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)

Assessment of the virologic response to doravirine at 100 mg, compared to efavirenz, each in combination with TRUVADA, as measured by the percentage of participants with plasma HIV-1 RNA \<200 copies/mL at Week 24. HIV RNA levels were determined using the Abbott RealTime HIV-1 Assay. The percentage of participants in any treatment group with a virologic response was primarily assessed for Weeks 0-24. The NC=F approach was used as the primary approach to handle missing data for this analysis of efficacy. This secondary outcome was analyzed for HIV-1 RNA \<200 copies/mL in Part I \& Part II combined.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Virologic Response (HIV-1 RNA <200 Copies/mL) at Week 24: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)
Percentage of participantsDoravirine 100 mg: Part I/II (Combined)Efavirenz 600 mg: Part I/II (Combined)
Percentage of Participants With Virologic Response (HIV-1 RNA <200 Copies/mL) at Week 24: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)89.7 (82.3 to 94.8)87.0 (79.2 to 92.7)
Statistical analysis
  • Doravirine 100 mg: Part I/II (Combined) vs Efavirenz 600 mg: Part I/II (Combined) · Difference in % response: 2.7 · 95% CI -6.1 to 11.7A positive value would be considered as favoring doravirine over efavirenz.
SecondaryPercentage of Participants With Virologic Response (HIV-1 RNA <200 Copies/mL) at Week 48: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)

Evaluation of the antiretroviral activity of doravirine at 100 mg, compared to efavirenz, each in combination with TRUVADA for 24 weeks, as measured by the percentage of participants with HIV-1 RNA \<200 copies/mL at Week 48. HIV RNA levels were determined using the Abbott RealTime HIV-1 Assay. This primary outcome was analyzed for RNA \<200 copies/mL in Part I \& Part II combined.

Time frame:
Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With Virologic Response (HIV-1 RNA <200 Copies/mL) at Week 48: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)
Percentage of participantsDoravirine 100 mg: Part I/II (Combined)Efavirenz 600 mg: Part I/II (Combined)
Percentage of Participants With Virologic Response (HIV-1 RNA <200 Copies/mL) at Week 48: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)85.2 (77.1 to 91.3)85.0 (76.9 to 91.2)
Statistical analysis
  • Doravirine 100 mg: Part I/II (Combined) vs Efavirenz 600 mg: Part I/II (Combined) · Difference in % response: 0.1 · 95% CI -9.7 to 9.9A positive value would be considered as favoring doravirine over efavirenz.
SecondaryPercentage of Participants With Virologic Response (HIV-1 RNA <200 Copies/mL) at Week 96: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)

Assessment of the virologic response to doravirine at 100 mg, compared to efavirenz, each in combination with TRUVADA, as measured by the percentage of participants with plasma HIV-1 RNA \<200 copies/mL at Week 96. HIV RNA levels were determined using the Abbott RealTime HIV-1 Assay. The percentage of participants in any treatment group with a virologic response was primarily assessed for Weeks 0-96. The Non-Completer = Failure (NC=F) approach, in which participants who prematurely discontinued assigned treatment for any reason and were considered as failures thereafter, was used as the primary approach to handle missing data this analysis of efficacy. This primary outcome was analyzed for HIV-1 RNA \<200 copies/mL in Part I \& Part II combined.

Time frame:
Week 96
Reported as:
Number · Percentage of participants
Percentage of Participants With Virologic Response (HIV-1 RNA <200 Copies/mL) at Week 96: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)
Percentage of participantsDoravirine 100 mg: Part I/II (Combined)Efavirenz 600 mg: Part I/II (Combined)
Percentage of Participants With Virologic Response (HIV-1 RNA <200 Copies/mL) at Week 96: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)79.6 (70.8 to 86.8)75.9 (66.7 to 83.6)
Statistical analysis
  • Doravirine 100 mg: Part I/II (Combined) vs Efavirenz 600 mg: Part I/II (Combined) · Difference in % response: 3.9 · 95% CI -7.3 to 15.0A positive value would be considered as favoring doravirine over efavirenz.
SecondaryChange From Baseline in CD4 T Lymphocyte Cell Count at Week 24: Doravirine (All Doses) vs Efavirenz (Part I)

Evaluation of the change from baseline in the CD4 cell count at Week 24 in participants receiving doravirine at all doses (25 mg, 50 mg, 100 mg, and 200 mg), compared with participants receiving efavirenz 600 mg. The Observed Failure (OF) approach was used to handle missing data, and the Baseline CD4 cell count was carried forward for participants who discontinued assigned treatment due to lack of efficacy.

Time frame:
Baseline, Week 24
Reported as:
Mean · cells/mm^3
Change From Baseline in CD4 T Lymphocyte Cell Count at Week 24: Doravirine (All Doses) vs Efavirenz (Part I)
cells/mm^3Doravirine 25 mg: Part IDoravirine 50 mg: Part IDoravirine 100 mg: Part IDoravirine 200 mg: Part IEfavirenz 600 mg: Part I
Change From Baseline in CD4 T Lymphocyte Cell Count at Week 24: Doravirine (All Doses) vs Efavirenz (Part I)154.1 (115.1 to 193.1)112.9 (74.5 to 151.2)133.6 (100.4 to 166.8)140.7 (95.6 to 185.7)121.1 (73.3 to 169.0)
Statistical analysis
  • Doravirine 25 mg: Part I vs Efavirenz 600 mg: Part I · Difference in cd4 change: 33.0 · 95% CI -28.1 to 94.0A positive value would be considered as favoring doravirine over efavirenz.
  • Doravirine 50 mg: Part I vs Efavirenz 600 mg: Part I · Difference in cd4 change: -8.3 · 95% CI -68.5 to 51.9A positive value would be considered as favoring doravirine over efavirenz.
  • Doravirine 100 mg: Part I vs Efavirenz 600 mg: Part I · Difference in cd4 change: 12.5 · 95% CI -44.6 to 69.5A positive value would be considered as favoring doravirine over efavirenz.
  • Doravirine 200 mg: Part I vs Efavirenz 600 mg: Part I · Difference in cd4 change: 19.6 · 95% CI -45.1 to 84.2A positive value would be considered as favoring doravirine over efavirenz.
SecondaryChange From Baseline in CD4 Cell Count at Week 24: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)

Assessment of the change from baseline in the CD4 cell count at Week 24 in participants receiving doravirine at 100 mg, compared with participants receiving efavirenz 600 mg. The OF approach was used to handle missing data, and the Baseline CD4 cell count was carried forward for participants who discontinued assigned treatment due to lack of efficacy.

Time frame:
Baseline, Week 24
Reported as:
Mean · cells/mm^3
Change From Baseline in CD4 Cell Count at Week 24: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)
cells/mm^3Doravirine 100 mg: Part I/II (Combined)Efavirenz 600 mg: Part I/II (Combined)
Change From Baseline in CD4 Cell Count at Week 24: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)152.3 (121.7 to 182.8)146.0 (113.1 to 178.8)
Statistical analysis
  • Doravirine 100 mg: Part I/II (Combined) vs Efavirenz 600 mg: Part I/II (Combined) · Difference in cd4 change: 6.3 · 95% CI -38.2 to 50.8A positive value would be considered as favoring doravirine over efavirenz.
SecondaryChange From Baseline in CD4 Cell Count at Week 48: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)

Assessment of the change from baseline in the CD4 count at Week 48 in participants receiving doravirine at 100 mg, compared with participants receiving efavirenz 600 mg. The OF approach was used to handle missing data, and the Baseline CD4 cell count was carried forward for subjects who discontinued assigned treatment due to lack of efficacy.

Time frame:
Baseline, Week 48
Reported as:
Mean · cells/mm^3
Change From Baseline in CD4 Cell Count at Week 48: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)
cells/mm^3Doravirine 100 mg: Part I/II (Combined)Efavirenz 600 mg: Part I/II (Combined)
Change From Baseline in CD4 Cell Count at Week 48: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)191.9 (160.8 to 223.1)194.5 (163.2 to 225.9)
Statistical analysis
  • Doravirine 100 mg: Part I/II (Combined) vs Efavirenz 600 mg: Part I/II (Combined) · Difference in cd4 change: -2.6 · 95% CI -46.5 to 41.3A positive value would be considered as favoring doravirine over efavirenz.
SecondaryChange From Baseline in CD4 Cell Count at Week 96: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)

A secondary endpoint in Part I/II combined was the change from baseline in the CD4 count at Week 96 in participants receiving doravirine at 100 mg, compared with participants receiving efavirenz 600 mg. The OF approach was used to handle missing data, and the Baseline CD4 cell count was carried forward for subjects who discontinued assigned treatment due to lack of efficacy.

Time frame:
Baseline, Week 96
Reported as:
Mean · cells/mm^3
Change From Baseline in CD4 Cell Count at Week 96: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)
cells/mm^3Doravirine 100 mg: Part I/II (Combined)Efavirenz 600 mg: Part I/II (Combined)
Change From Baseline in CD4 Cell Count at Week 96: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)259.2 (220.0 to 298.3)263.6 (218.1 to 309.1)
Statistical analysis
  • Doravirine 100 mg: Part I/II (Combined) vs Efavirenz 600 mg: Part I/II (Combined) · Difference in cd4 change: -4.4 · 95% CI -64.0 to 55.1A positive value would be considered as favoring doravirine over efavirenz.
SecondaryPercentage of Participants With At Least 1 AE in Weeks 0-48: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)

A secondary outcome in Part I/II combined was the percentage of participants receiving doravirine at 100 mg, compared with participants receiving efavirenz 600 mg, who had at least 1 AE over 48 weeks of treatment. The percentage of participants in any treatment group with at least 1 AE was primarily assessed for Weeks 0-48.

Time frame:
Up to Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With At Least 1 AE in Weeks 0-48: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)
Percentage of participantsDoravirine 100 mg: Part I/II (Combined)Efavirenz 600 mg: Part I/II (Combined)
Percentage of Participants With At Least 1 AE in Weeks 0-48: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)87.0 (79.2 to 92.7)89.8 (82.5 to 94.8)
Statistical analysis
  • Doravirine 100 mg: Part I/II (Combined) vs Efavirenz 600 mg: Part I/II (Combined) · Difference: -2.8 · 95% CI -11.7 to 6.0A negative value would be considered as favoring doravirine over efavirenz.
SecondaryPercentage of Participants With At Least 1 AE in Weeks 0-96: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)

A secondary outcome in Part I/II combined was the percentage of participants receiving doravirine at 100 mg, compared with participants receiving efavirenz 600 mg, who had at least 1 AE over 96 weeks of treatment. The percentage of participants in any treatment group with at least 1 AE was primarily assessed for Weeks 0-96.

Time frame:
Up to Week 96
Reported as:
Number · Percentage of participants
Percentage of Participants With At Least 1 AE in Weeks 0-96: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)
Percentage of participantsDoravirine 100 mg: Part I/II (Combined)Efavirenz 600 mg: Part I/II (Combined)
Percentage of Participants With At Least 1 AE in Weeks 0-96: Doravirine 100 mg vs Efavirenz (Part I & Part II Combined)89.8 (82.5 to 94.8)96.3 (90.8 to 99.0)
Statistical analysis
  • Doravirine 100 mg: Part I/II (Combined) vs Efavirenz 600 mg: Part I/II (Combined) · Difference: -6.5 · 95% CI -14.1 to 0.3A negative value would be considered as favoring doravirine over efavirenz.

Adverse events

Collected over 96 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Doravirine 25 mg (n=40)—4/40 (10%)31/40 (77.5%)
Doravirine 50 mg (n=43)—1/43 (2.3%)35/43 (81.4%)
Doravirine 100 mg (n=108)—11/108 (10.2%)78/108 (72.2%)
Doravirine 200 mg (n=41)—3/41 (7.3%)36/41 (87.8%)
Efavirenz 600 mg: Part I (n=108)—13/108 (12%)82/108 (75.9%)
Most frequent serious events
Showing 10 of 35
Most frequent serious events
EventDoravirine 25 mg (n=40)Doravirine 50 mg (n=43)Doravirine 100 mg (n=108)Doravirine 200 mg (n=41)Efavirenz 600 mg: Part I (n=108)
Cholecystitis acuteHepatobiliary disorders1/400/430/1080/410/108
Acute hepatitis CInfections and infestations1/400/430/1080/410/108
CellulitisInfections and infestations1/400/430/1080/410/108
PneumoniaInfections and infestations1/400/430/1081/410/108
CardiomyopathyCardiac disorders0/400/430/1081/410/108
Pericardial effusionCardiac disorders0/400/430/1081/410/108
Biliary dyskinesiaHepatobiliary disorders0/400/430/1081/410/108
Cryptosporidiosis infectionInfections and infestations0/400/430/1081/410/108
Pleural effusionRespiratory, thoracic and mediastinal disorders0/400/430/1081/410/108
PharyngotonsillitisInfections and infestations0/401/430/1080/411/108
Most frequent other events
Showing 10 of 44
Most frequent other events
EventDoravirine 25 mg (n=40)Doravirine 50 mg (n=43)Doravirine 100 mg (n=108)Doravirine 200 mg (n=41)Efavirenz 600 mg: Part I (n=108)
DizzinessNervous system disorders5/405/4316/1083/4132/108
NasopharyngitisInfections and infestations3/405/4319/10812/4113/108
DiarrheaGastrointestinal disorders10/404/4316/1085/4118/108
NauseaGastrointestinal disorders3/407/4313/1089/4111/108
Abnormal dreamsPsychiatric disorders5/409/437/1084/4119/108
FatigueGeneral disorders7/405/436/1085/417/108
HeadacheNervous system disorders5/406/4314/1087/4115/108
InfluenzaInfections and infestations6/402/433/1085/412/108
SyphilisInfections and infestations4/401/436/1086/418/108
InsomniaPsychiatric disorders1/406/4310/1083/416/108

Baseline characteristics

All Treated participants randomized to doravirine or efavirenz using an interactive voice response system (IVRS)

Age, Continuous
Age, Continuous(years)Doravirine 25 mg: Part I/II CombinedDoravirine 50 mg Part I/II CombinedDoravirine 100 mg: Part I/II CombinedDoravirine 200 mg: Part I/II CombinedEfavirenz 600 mg: Part I/II CombinedTotal
Mean38.9 ± 13.4238.3 ± 10.7136.8 ± 11.3134.4 ± 8.8535.2 ± 9.0836.4 ± 10.62
Sex: Female, Male
Sex: Female, Male(Participants)Doravirine 25 mg: Part I/II CombinedDoravirine 50 mg Part I/II CombinedDoravirine 100 mg: Part I/II CombinedDoravirine 200 mg: Part I/II CombinedEfavirenz 600 mg: Part I/II CombinedTotal
Female2691725
Male38379940101315
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Gatell JM, Morales-Ramirez JO, Hagins DP, Thompson M, Arasteh K, Hoffmann C, Raffi F, Osiyemi O, Dretler R, Harvey C, Xu X, Plettenberg A, Smith DE, Portilla J, Rugina S, Kumar S, Frobose C, Wan H, Rodgers A, Hwang C, Teppler H. Doravirine dose selection and 96-week safety and efficacy versus efavirenz in antiretroviral therapy-naive adults with HIV-1 infection in a Phase IIb trial. Antivir Ther. 2019;24(6):425-435. doi: 10.3851/IMP3323. PubMed 31355775 ↗
  • Thompson M, Orkin C, Molina JM, Sax P, Cahn P, Squires K, Xu X, Rodgers A, Kumar S, Teppler H, Martin E, Hanna G, Hwang C. Once-daily Doravirine for Initial Treatment of Adults Living With Human Immunodeficiency Virus-1: An Integrated Safety Analysis. Clin Infect Dis. 2020 Mar 17;70(7):1336-1343. doi: 10.1093/cid/ciz423. PubMed 31121013 ↗

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2012 to primary completion in Dec 2014, 25 months.

Results were first posted in Dec 2017, 3 years after primary completion.

Of 34 industry-sponsored phase 2 interventional studies under HIV Infections, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's 25 months is above that.

Counting every sponsor, half of 99 studies reached it within 31 months; a quarter within 17 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2012
First posted
Jul 2, 2012
StartActual
Oct 12, 2012
Primary completionActual
Dec 3, 2014
CompletionActual
Mar 21, 2016
Results first posted
Dec 13, 2017
Last update
Jul 18, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01632345
Responsible party
Sponsor
First posted
Jul 2, 2012
Start date
Oct 12, 2012
Primary completion
Dec 3, 2014
Completion
Mar 21, 2016
Results posted
Dec 13, 2017
Last update
Jul 18, 2019

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Doravirine

Start the discussion